Preliminary Studies on Proteomics and Peritoneal Dialysis Reference: Brewis IA, Topley N. Proteomics and peritoneal dialysis: Early days but clear potential.

Slides:



Advertisements
Similar presentations
Parkinson’s disease (PD) is one of the most common chronic progressive neurodegenerative diseases. PD has a prevalence of 1.2 million people in Europe.
Advertisements

Protein Quantitation II: Multiple Reaction Monitoring
The Proteomics Core at Wayne State University
Nuevas Soluciones en DP, Sirven? Prueba en diabéticos con transporte peritoneal alto y promedio alto Dr. José Ramón Paniagua Sierra Unidad de Investigación.
Calcium & phosphor disturbance CKD- MBD Dr. Atapour.
Safety and Extrapolation Steven Hirschfeld, MD PhD Office of Cellular, Tissue and Gene Therapy Center for Biologics Evaluation and Research FDA.
Staff Oncologist, Mayo Clinic Arizona
Will Peritoneal Dialysis Modality Make a Difference in Peritonitis? Reference: Piraino B, Sheth H. Peritonitis – Does peritoneal dialysis modality make.
POLYOMAVIRUS INFECTION IN RENAL ALLOGRAFTS: PROGRESS SINCE BANFF 1999 Parmjeet Randhawa Associate Professor Division of Transplantation Pathology Department.
Metabonomics A New Potential Diagnostic Tool David Huffman Western Michigan University WDA 2010.
Microarrays: Tools for Proteomics
Biomarker studies in advanced breast cancer Dr Phil Murray (CHUFT) & Dr Dawn Farrar (UOE)
Introduction of Cancer Molecular Epidemiology Zuo-Feng Zhang, MD, PhD University of California Los Angeles.
OMICS Group Contact us at: OMICS Group International through its Open Access Initiative is committed to make genuine and.
Proteomics Understanding Proteins in the Postgenomic Era.
Thoughts on Biomarker Discovery and Validation Karla Ballman, Ph.D. Division of Biostatistics October 29, 2007.
Genetic Diseases. Objectives  To recap genetic inheritance  To identify four genetic diseases  To review key factors to study  To propose research.
Luděk Bláha, PřF MU, RECETOX BIOMARKERS AND TOXICITY MECHANISMS 13 – BIOMARKERS Summary and final notes.
The Nature of Disease.
Non-Surgical Periodontal Therapy Reduces Coronary Heart Disease Risk Markers: A Randomized Controlled Trial Bokhari SAH, Khan AA, Butt AK, Azhar M, Hanif.
Dr. Charu Kartik Senior Clinical Dietitian KFSH&RC,Riyadh Dr. Charu Kartik Senior Clinical Dietitian KFSH&RC,Riyadh NUTRITIONAL CO-MORBITIES POST RENAL.
Marcora Mandreoli Antonio Santoro U.O.C. di Nefrologia, Dialisi ed Ipertensione Policlinico S.Orsola-Malpighi Bologna - ITALY Azienda Ospedaliero-Universitaria.
©2013 Astute Medical, Inc. PN 0138 Rev B 2013/03/19
2007 GeneSpring MS GeneSpring for Metabolite BioMarker Analysis using Mass Spectrometry data Agilent Q-TOF VIP Visit Jan 16-17, 2007 Santa Clara, CA Thon.
Peritoneal Dialysis for Elderly Patients: A Review Source: Tesar V. Peritoneal dialysis in the elderly—is its underutilization justified? Nephrol Dial.
False Biomarker Discovery due to Reactivity of a Commercial ELISA for CUZD1 with Cancer Antigen CA125 I. Prassas, D. Brinc, S. Farkona, F. Leung, A. Dimitromanolakis,
Optimizing Nutrition Therapy
Metrological Experiments in Biomarker Development (Mass Spectrometry—Statistical Issues) Walter Liggett Statistical Engineering Division Peter Barker Biotechnology.
1 Biochemistry & medicine introduction. 2 1 、 definition  Science concerned with chemical basis of life.
Symposium 18 Tools for Measuring Early Lung Disease Proteomic biomarkers of Lower Airway Disease Frank Accurso, MD Professor of Pediatrics CF Center Director.
C 2.2 and 2.3: Role of Membrane in Transport and Applications of Cellular Transport in Industry and Medicine Science 10.
A Comparison of Albumin and Saline for Fluid Resuscitation in the Intensive Care Unit The SAFE Study Investigators N Engl J Med 2004: 350:
· Lecture 31 & 32 : Scope of clinical biochemistry ط Uses of clinical biochemistry tests ط Diagnosis, Prognosis, Screening, Monitoring ط Reporting results.
TAP(Tandem Affinity Purification) Billy Baader Genetics 677.
Autoimmunity and Type I Diabetes CCMD 793A: Fundamental Integrated SystemsFALL, 2006 James M. Sheil, Ph.D.
Chronic renal failure and common accompanying diseases Hradec Králové, November 2007 © by Adrian Franke.
Dr. Jeyaparvathi Somasundaram
Copyright © 2016 McGraw-Hill Education. All rights reserved. No reproduction or distribution without the prior written consent of McGraw-Hill Education.
Cancers of the Digestive System November 19, 2007 NCDD Meeting Chair: John M. Carethers, MD Vice Chair: Robert Sandler, MD, MPH.
PLANT BIOTECHNOLOGY & GENETIC ENGINEERING (3 CREDIT HOURS) LECTURE 13 ANALYSIS OF THE TRANSCRIPTOME.
Inflammatory Bowel Diseases November 19, 2007 NCDD Meeting Chair: Daniel K. Podolsky, MD Vice Chair: Eugene B. Chang, MD.
 Routine viral diagnostics: indirect and direct detection of viruses. ◦ Indirect detection: serological tests; ◦ Direct detection:  Viral antigens;
CRP C-Reactive Protein. CRP One of many Acute Phase Proteins Produced in response to trauma, tissue damage, infection and inflammation Produced in response.
 Visual exam A laboratory technician will examine the urine's appearance. Urine is typically clear. Cloudiness or unusual  odor may indicate a problem.
© OCR 2016 Treating kidney failure. © OCR 2016 Objectives of lesson Describe the symptoms and causes of kidney failure Explain methods of diagnosing kidney.
Risk Involved with Dual RAAS Blockade in Kidney Disease Source: Bakris GL. Dual RAAS blockade is desirable in kidney disease: Con. Kidney Int. 2010;78:546–549.
What is proteomics? Richard Mbasu and Ben Richards.
Different microarray applications Rita Holdhus Introduction to microarrays September 2010 microarray.no Aim of lecture: To get some basic knowledge about.
Research Methodology Proposal Prepared by: Norhasmizawati Ibrahim (813750)
Elise Casteleyn, June 2015 DBS Project Biochemistry Laboratory - Regional Clinical Proteomics Platform Dried blood spot, a new method for the quantification.
Risk Factors for Linezolid-Associated Thrombocytopenia in Adult Patients Cristina Gervasoni Ospedale Luigi Sacco, Milano.
Novel blood and tissue Biomarkers for Breast and Prostate Cancers
European Patients’ Academy on Therapeutic Innovation Challenges in Personalised Medicine.
Shotgun protein identification Creative Proteomics offers iTRAQ protein quantification service suited for unbiased untargeted biomarker discovery. Relative.
Richard Mbasu and Ben Richards
OMICS Journals are welcoming Submissions
* Potential use of HP and AMBP in urine for the screening of prostate cancer Sanja Kiprijanovska1, Selim Komina2, Gordana Petrusevska2,
Proteomic Analysis post Acute Spinal Cord Injury in human
The CANUSA Trial Reference
Volume 85, Issue 4, Pages (April 2014)
The discovery and validation of kidney injury-related
FIGURE 1: Urinary proteome analysis in nephrology
Protein/Peptide Quantification
Human Health and Disease
Mining the human urine proteome for monitoring renal transplant injury
A perspective on proteomics in cell biology
Types of biomarkers/biosignatures to be used for cardiovascular disease. Types of biomarkers/biosignatures to be used for cardiovascular disease. There.
Volume 85, Issue 4, Pages (April 2014)
Presentation transcript:

Preliminary Studies on Proteomics and Peritoneal Dialysis Reference: Brewis IA, Topley N. Proteomics and peritoneal dialysis: Early days but clear potential. Nephrol Dial Transplant. 2010;25:1749–1753.

Global Analysis of Proteomics Proteomics and its application have lead the post-genomic technologies, as it has helped in the understanding the central role of proteins and protein–protein interactions in the entire aspects of cellular function. Quantification and global identifications of proteins, not only help in understanding a diseased or healthy individual but also lead to the discovery of biomarkers. Biomarker discovery has profuse scientific evidence from proteomics and suggests that most of the diseases are caused due to changes in certain proteins in the plasma. The clinical specimen or biological fluids probably contain a protein profile, which indicates diseases in that organ system like studies on urine can be related to kidney and bladder diseases, cerebrospinal fluid for neurological conditions.

Proteomics to Study Peritoneal Dialysis Paucity of data is the main reason for few studies on peritoneal effusions. Peritoneal dialysis is considered as an effective mode of renal replacement therapy. This offers analysis of peritoneal dialysis effluents (PDE) from all types of patients and can also provide critical information about PD exclusively, along with general information about the peritoneal environment. A study from this paper was the first to show the differences between diabetic PDE and normal peritoneal fluid.

The methods involved two dimensional electrophoresis (2DE); a gel-based approach for the analysis of proteins and was later confirmed by western blotting. Inclusions like vitamin D-binding protein, haptoglobin and α2- macroglobulin at raised levels, and complement component C4A and immunoglobulin κ at lower levels were considered and confirmed through western blotting. Change in the permeability of the peritoneal membrane, caused by the loss of vitamin binding protein, haptoglobin and α2-macroglobulin leads to loss and leakage of medium-sized protein. This paper also proposes that peritoneal membrane scleroses are caused due to certain mechanisms. Differentiation and identification of proteins in diabetic PDE and normal fluid will surely help in further studies.

Another sophisticated methodology, gel electrophoresis then liquid chromatography-mass spectrometry (GeLC-MS) was considered with nine pediatric PD patients for the identification of 189 PDE proteins. Different levels of C4A and immunoglobulin κ were shown in 20 chronic PD patients with altering transport rates. Identification of 5 proteins was done at different levels among the transport groups after 2DE. Increased levels of C4A and immunoglobulin κ in higher transport vs. lower transport patients were confirmed, in particular by further validation set of 24 patients by ELISA. This further emphasizes that proteomics can be used in comparing differences in different subgroups.

Analysis revealed that these proteins were derived from the extracellur matrix, suggesting retention of PD fluid within the extracellular matrix. Thus, information about the localization and changes in proteins in the peritoneal membrane is provided by proteomics. Proteomics technology has lead to the discovery of unknown proteins like gelsolin and intelectin. Gelsolin plays a role in protecting mesothelial cell damage against infection and is used as a marker in sepsis. Intelectin has a defensive role against permeable intestinal bacteria and parasites in the peritoneal cavity.

Time Now for more Extended Studies Till date only initial studies have been carried out, and prospective studies involving greater number of patients is required for more information about the changes in the peritoneal dialysate proteins that are associated with particular phenotypes like nutritional status, risk of peritoneal infection, membrane function, residual renal function and fibrosis. This information can be used for further advanced analysis. Less number of proteins is identified till date with majority of the proteins yet to be discovered. With the present expensive and technically challenging ways, efforts are emphasized on identification of novel proteins to enable new hypothesis to be formed or identification of novel prospective biomarkers, through a range of workflow choices. In addition, proteomics technology has adapted 2DE-based difference gel electrophoresis (DIGE) or Lcbased MS labeling workflows, such as isobaric tags for relative and absolute quantification (iTRAQ) as gold standards for relative protein quantification.

The Achilles’ Heel of Proteomics Analysis of biological fluids is not an easy process and the potential of biological marker discovery is limited, as it is a challenging process and this has lead to the lowest discovery. A difference of 10 orders of magnitude is observed among largely and the least abundant proteins in the biological fluids. The available analytical technologies have 2–4 orders of magnitude dynamic range for protein detection. This suggests that there is a deficit and hence not all proteins can be discovered using these methods. Still these methods have importance as they can be used in the identification of proteins, which had not been previously identified. Although certain sample fractionation approaches can be used to improve specificity, hypothetical changes are essential in proteomics technology in the discovery of all proteins.

Looking into the Future Preliminary studies on PDE proteomics promotes understanding PD. Function of the kidney, pathological damage of the peritoneum can be identified without invasive techniques. Discovery of biomarkers helps in measuring peritoneal damage and changes in transport through noninvasive methods. In addition to this, the effect of different dialysis fluids and prolonged PD period on protein profiles might also be investigated to offer better understanding of the pathological processes. Advanced studies are guaranteed in this field for better diagnosis, prognosis and therapeutic monitoring of pathological processes. Proteomics is a podium in providing assistance in both understanding and utilization of PD.

Comprehensive Basket in Anemia Management